阿替唑单抗
伦瓦提尼
贝伐单抗
医学
耐受性
肝细胞癌
肿瘤科
内科学
癌症
不利影响
无容量
化疗
免疫疗法
索拉非尼
作者
Daisuke Kato,Takanori Suzuki,Kentaro Matsuura,Kohei Okayama,Fumihiro Okumura,Yoshihito Nagura,Satoshi Sobue,Katsumi Hayashi,Atsunori Kusakabe,Izumi Hasegawa,Sho Matoya,Tsutomu Mizoshita,Yoshihide Kimura,Hiromu Kondo,Atsushi Ozasa,Hayato Kawamura,Kei Fujiwara,Shunsuke Nojiri,Hiromi Kataoka
出处
期刊:Oncology
[S. Karger AG]
日期:2024-10-18
卷期号:: 1-9
摘要
We investigated the effectiveness of lenvatinib (LEN) after disease progression following first-line treatment with atezolizumab plus bevacizumab (Atez/Bev) in patients with unresectable hepatocellular carcinoma (HCC).
科研通智能强力驱动
Strongly Powered by AbleSci AI